MONTCLAIR, N.J., July 18, 2016 /PRNewswire/ -- Nexus BioPharma, Inc., (OTC-BB: NEXS), a company specializing in the development of a weight loss drug therapy, announced today the appointment of Daniel Einhorn, M.D. to the Company's Scientific & Clinical Advisory Board. Dr. Einhorn is medical director of the Scripps Whittier Diabetes Institute, Clinical Professor of Medicine (voluntary) at UC San Diego, President of Diabetes and Endocrine Associates, and Associate Editor of the Journal of Diabetes.
Dr. Einhorn's experience includes acting as a trustee and past-president of the American College of Endocrinology (ACE), a founding member and current regent of the ACE Foundation, and past-president of the American Association of Clinical Endocrinologists (AACE). He received his BA at Yale (Summa cum Laude), his MD at Tufts (AOA) and his post-graduate training at Harvard. He has been in leadership at AACE and ACE for over 20 years during which time he has participated in writing many national guidelines, including those for diabetes, pre-diabetes, inpatient diabetes management, and obesity. Dr. Einhorn has been on the teaching faculty of every AACE/ACE annual meeting since 1994, chairing the meeting in 2009, and he continues to be a practicing physician.
"We are thrilled that Dan is joining our team of advisors," said Mr. Warren C. Lau, Chief Executive Officer and President of Nexus BioPharma, Inc. "His background and experience will be invaluable as we move our weight loss product candidate into later stage clinical development for treating obesity and type 2 diabetes."
"We need better tools to manage obesity and metabolic diseases, like diabetes," said Dr. Einhorn. "Innovative ideas often come from unexpected pathways."
Nexus BioPharma, Inc. is developing a proprietary drug that activates a key metabolic pathway, the same pathway activated by intense physical exercise.
About Nexus BioPharma, Inc. www.nexusbiopharma.com
Nexus BioPharma, Inc. is a preclinical stage biotechnology company developing new therapies and intellectual property from research and development activities for treating obesity and type 2 diabetes.
The main target for the company's research is the adenosine monophosphate-activated protein kinase (AMPK) pathway. When activated, results include increased metabolism, reduced fat mass and improved blood chemistry.
The underlying biochemistry is described in an article from the journal Cell Metabolism by Claire C. Bastie, and Jeffrey E. Pessin, entitled "Fyn-Dependent Regulation of Energy Expenditure and Body Weight Is Mediated by Tyrosine Phosphorylation of LKB1". Cell Metab. 2010 Feb 3;11(2):113-24
In completed pre-clinical trials of the pharmaceutical activation of the AMPK pathway, test subjects showed reduced fat mass with no loss of lean muscle mass, plus a higher rate of energy expenditure, increased insulin sensitivity, increased fatty acid oxidation, improved plasma and tissue triglyceride levels, with lower cholesterol. Upon translation of this pharmaceutical activation to humans, these effects are expected to have a significant impact on treating obesity and diabetes.
Cautionary Statement Regarding Forward-Looking Information
This press release may contain certain "forward-looking statements" relating to the business of Nexus BioPharma, and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements regarding: the impact of the proceeds from the private placement on the Company's short term business and operations,; the general ability of the Company to achieve its commercial objectives, including the ability of the Company to sustain growth; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
SOURCE Nexus BioPharma, Inc.